Basic information Safety Supplier Related

BUTYROLACTONE I

Basic information Safety Supplier Related

BUTYROLACTONE I Basic information

Product Name:
BUTYROLACTONE I
Synonyms:
  • BUTYROLACTONE I
  • 2,5-Dihydro-4-hydroxy-2-[4-hydroxy-3-(3-methyl-2-butenyl)benzyl]-3-(4-hydroxyphenyl)-5-oxofuran-2-carboxylic acid methyl ester
  • OloMoucin
  • 2-Furancarboxylic acid, 2,5-dihydro-4-hydroxy-2-[[4-hydroxy-3-(3-methyl-2-buten-1-yl)phenyl]methyl]-3-(4-hydroxyphenyl)-5-oxo-, methyl ester, (2R)-
  • Butyrolactone I - CAS 87414-49-1
  • Butyrolactone I, ATP-competitive cyclin-dependent kinase (CDK) inhibitor
CAS:
87414-49-1
MF:
C24H24O7
MW:
424.44
Product Categories:
  • Antibiotic
Mol File:
87414-49-1.mol
More
Less

BUTYROLACTONE I Chemical Properties

Melting point:
74℃
Boiling point:
660.1±55.0 °C(Predicted)
Density 
1.353±0.06 g/cm3(Predicted)
RTECS 
LU0221600
storage temp. 
Store at -20°C
solubility 
Soluble in ethanol at 25mg/ml or DMSO at 10mg/ml
form 
White solid.
pka
8.59±0.40(Predicted)
color 
White to off-white
Sensitive 
Light Sensitive
More
Less

Safety Information

HS Code 
29419000
More
Less

BUTYROLACTONE I Usage And Synthesis

Uses

Butyrolactone I is one of a family of three butyrolactones isolated from Aspergillus fumigatus, first reported in 1983. Butyrolactone I exhibits antitumor activity, inhibiting the cell cycle at the G1/S and G2/M transitions. Butyrolactone I is a selective inhibitor of cyclin-dependent kinases CDK1/cyclin B, CDK2 and CDK5, and is an important bioprobe for understanding the cellular roles of CDKs.

Biological Activity

Cell permeable: yes', 'Primary Target
p34cdk1/cyclinB', 'Product does not compete with ATP.', 'Reversible: no', 'Target IC50: 680 nM against Cdk1

Enzyme inhibitor

This natural product (FW = 424.45 g/mol), first identified in species of Aspergillus and named systematically as 2,5-dihydro-4-hydroxy 2-([4- hydroxy-3-(3-methyl-2-butenyl)phenyl]methyl)-3-(4-hydroxyphenyl)-5-oxo- 2-furancarboxylic acid methyl ester, competes with ATP in cyclindependent kinase reactions. The IC50 values for these kinases are typically 0.6-1.5 μM. Butyrolactone I also inhibits cell proliferation by the inhibiting pRb phosphorylation in IMR32 cells, causing both G1 and G2 arrest and stimulating apoptosis. Target(s): cyclin-dependent kinases 1 and 2; cdk5; protein kinase C; protein kinase A; MAP kinase; casein kinase II; [tau protein] kinase.

in vivo

Butyrolactone-I (1-5 mg/kg, p.o., 14 days) ameliorates heat-stress-induced apoptosis in mice through the ROS/PERK/CHOP signaling pathway[3].
Butyrolactone-I (1-5 mg/kg, p.o., 14 days) alleviates intestinal barrier damage caused by DSS through regulating lactobacillus johnsonii and its metabolites in mice[6].
Butyrolactone I (10-40 mg/kg, p.o., from the 17th week to 24th week) attenuates inflammation in murine NASH by inhibiting the NF-κB signaling pathway[7].

Animal Model:Male C57BL/6J mice (heat-stressed)[3]
Dosage:1, 5 mg/kg
Administration:Oral gavage (p.o.), 14 days
Result:Downregulated HSP70 mRNA and mitigated weight loss.
Returned water intake and body temperature to normal levels.
Increased colon length.
Decreased Bax mRNA.
Inhibited the increases in the ROS and MDA levels.
Inhibited endoplasmic reticulum stress (ERS).
Inhibited p-PERK/PERK, p-eIF2α/eIF2α, ATF4, and CHOP.

IC 50

CDK1

storage

+4°C

BUTYROLACTONE ISupplier

Shanghai Winherb Medical Technology Co., Ltd.
Tel
021-38218169 13341702378
Email
winherb@126.com
Shanghai EFE Biological Technology Co., Ltd.
Tel
021-65675885 18964387627
Email
info@efebio.com
Shanghai YuanYe Biotechnology Co., Ltd.
Tel
021-61312847; 18021002903
Email
3008007409@qq.com
Lynnchem
Tel
86-(0)29-85992781 17792393971
Email
info@lynnchem.com
Novachemistry
Tel
44-20819178-90 02081917890
Email
info@novachemistry.com
More
Less

BUTYROLACTONE I(87414-49-1)Related Product Information